{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:54:23Z","timestamp":1781607263349,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this study is to examine the efficacy of 500\u00a0mg levofloxacin and 3\u00a0g fosfomycin given as single-dose prophylactic antibiotics one hour before urodynamic studies (UDS) to prevent urinary tract infections (UTIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-blinded, randomized clinical trial included 126 patients who underwent UDS between December 2022 and March 2024 at two urology centers in Jakarta. The patients, aged 18 years and older, were randomized equally into two groups receiving either 500\u00a0mg levofloxacin or 3\u00a0g fosfomycin prior to UDS. The primary indications for UDS included lower urinary tract symptoms (LUTS) (54.8%), overactive bladder (OAB) (32.8%), underactive bladder (8.9%), and stress urinary incontinence (3.5%). Three days post-UDS, patients were followed up with urinalysis and clinical assessment for UTI symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 126 patients, UTI was diagnosed in 26 cases (20.9%), with 14 cases (22.2%) in the levofloxacin group and 12 cases (19%) in the fosfomycin group, showing no significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.660). Symptomatic UTIs occurred in 6 patients (4.8%) in the levofloxacin group and 7 patients (5.6%) in the fosfomycin group. E. coli was the most commonly detected bacterium in urine cultures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our center, there was no significant difference in the clinical outcome between the administration of 3\u00a0g fosfomycin and 500\u00a0mg levofloxacin as single-dose prophylactic antibiotics prior to UDS. Given the rising antibiotic resistance, fosfomycin may be considered an alternative. Further multicenter and multinational studies are warranted, as bacterial profiles and antibiotic resistance patterns may vary across different regions and healthcare systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT06017479.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Registration Date<\/jats:title>\n                    <jats:p>2023-08-24.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-01839-y","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T05:51:20Z","timestamp":1752472280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the effectiveness of single-dose levofloxacin with single-dose fosfomycin pre-urodynamic study related to the incidence of urinary tract infection: a randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Harrina Erlianti","family":"Rahardjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fina","family":"Widia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Leonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Tanjung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hanif","family":"Arfiananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah Nuwwaaridya","family":"Fitriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmat Aidil Fajar","family":"Siregar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andika","family":"Afriansyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"2","key":"1839_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/tcmj.tcmj_19_17","volume":"29","author":"YH Jiang","year":"2017","unstructured":"Jiang YH, Kuo HC. Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence. Tzu Chi Med J. 2017;29(2):72\u20138. https:\/\/doi.org\/10.4103\/tcmj.tcmj_19_17.","journal-title":"Tzu Chi Med J"},{"issue":"1","key":"1839_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.22088\/cjim.11.1.100","volume":"11","author":"Z Ghanbari","year":"2020","unstructured":"Ghanbari Z, Haghollahi F, Eftekhr T, et al. Rate of urinary tract infection after urodynamic study in pelvic floor clinic. Casp J Intern Med. 2020;11(1):100\u20134. https:\/\/doi.org\/10.22088\/cjim.11.1.100.","journal-title":"Casp J Intern Med"},{"issue":"4","key":"1839_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.1464-410X.1999.00924.x","volume":"83","author":"L Bombieri","year":"1999","unstructured":"Bombieri L, Dance DAB, Rienhardt GW, Waterfield A, Freeman RM. Urinary tract infection after urodynamic studies in women: incidence and natural history. BJU Int. 1999;83(4):392\u20135. https:\/\/doi.org\/10.1046\/j.1464-410X.1999.00924.x.","journal-title":"BJU Int"},{"issue":"2","key":"1839_CR4","first-page":"84","volume":"48","author":"HE Rahardjo","year":"2016","unstructured":"Rahardjo HE, Tirtayasa PMW, Afriansyah A, Parikesit D, Akbar MI. The effectiveness of a three day course antibiotic Post-urodynamic study in preventing lower urinary tract infection. Acta Med Indones. 2016;48(2):84\u201390.","journal-title":"Acta Med Indones"},{"issue":"3","key":"1839_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.22037\/uj.v19i.7288","volume":"20","author":"HE Rahardjo","year":"2023","unstructured":"Rahardjo HE, Widia F, Manurung MA, et al. Comparison of the effectiveness of Pre-urodynamic Single-dose Levofloxacin with Post-urodynamic Levofloxacin for three days related to the incidence of urinary tract infection: A randomized controlled trial. Urol J. 2023;20(3):167\u201372. https:\/\/doi.org\/10.22037\/uj.v19i.7288.","journal-title":"Urol J"},{"key":"1839_CR6","doi-asserted-by":"publisher","first-page":"9681632","DOI":"10.1155\/2020\/9681632","volume":"2020","author":"Y Rosana","year":"2020","unstructured":"Rosana Y, Ocviyanti D, Halim M, et al. Urinary tract infections among Indonesian pregnant women and its susceptibility pattern. Infect Dis Obstet Gynecol. 2020;2020:9681632. https:\/\/doi.org\/10.1155\/2020\/9681632.","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"12","key":"1839_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2013-004152","volume":"3","author":"LD Qiao","year":"2013","unstructured":"Qiao LD, Chen S, Yang Y, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in china: data from a multicenter study. BMJ Open. 2013;3(12):1\u20137. https:\/\/doi.org\/10.1136\/bmjopen-2013-004152.","journal-title":"BMJ Open"},{"key":"1839_CR8","unstructured":"Kumalawati J, Handimulya D, Solin R. Bacterial and Antibiotics Susceptibility Profile at Cipto Mangunkusumo General Hospital July - Desember 2021.; 2021."},{"key":"1839_CR9","doi-asserted-by":"publisher","unstructured":"Wu XY, Cheng Y, Xu SF, Ling Q, Yuan XY, Du GH. Prophylactic Antibiotics for Urinary Tract Infections after Urodynamic Studies: A Meta-Analysis. Biomed Res Int. 2021;2021. https:\/\/doi.org\/10.1155\/2021\/6661588","DOI":"10.1155\/2021\/6661588"},{"issue":"12","key":"1839_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0220265","volume":"14","author":"IA Critchley","year":"2019","unstructured":"Critchley IA, Nicole Cotroneo, Pucci MJ, Rodrigo Mendes. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the united States in 2017. PLoS ONE. 2019;14(12):1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0220265.","journal-title":"PLoS ONE"},{"key":"1839_CR11","doi-asserted-by":"publisher","unstructured":"Limato R, Lazarus G, Dernison P, et al. Optimizing antibiotic use in indonesia: A systematic review and evidence synthesis to inform opportunities for intervention. Lancet Reg Heal - Southeast Asia. 2022;2(6). https:\/\/doi.org\/10.1016\/j.lansea.2022.05.002.","DOI":"10.1016\/j.lansea.2022.05.002"},{"issue":"6","key":"1839_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.kjms.2012.06.001","volume":"29","author":"C G\u00fcrb\u00fcz","year":"2013","unstructured":"G\u00fcrb\u00fcz C, G\u00fcner B, At\u015f G, Canat L, Ca\u015fkurlu T. Are prophylactic antibiotics necessary for urodynamic study? Kaohsiung J Med Sci. 2013;29(6):325\u20139.","journal-title":"Kaohsiung J Med Sci"},{"issue":"3","key":"1839_CR13","doi-asserted-by":"publisher","first-page":"S1339","DOI":"10.1016\/j.ajog.2021.12.120","volume":"226","author":"AA Jackson","year":"2022","unstructured":"Jackson AA, Ackerman C, Alesna N, et al. Risk of urinary tract infection after urodynamic studies in patients with recurrent urinary tract infection. Am J Obstet Gynecol. 2022;226(3):S1339. https:\/\/doi.org\/10.1016\/j.ajog.2021.12.120.","journal-title":"Am J Obstet Gynecol"},{"key":"1839_CR14","doi-asserted-by":"publisher","unstructured":"Zhou Y, Zhou Z, Zheng L, et al. Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options. Int J Mol Sci. 2023;24(13). https:\/\/doi.org\/10.3390\/ijms241310537.","DOI":"10.3390\/ijms241310537"},{"key":"1839_CR15","doi-asserted-by":"publisher","unstructured":"Lee DS, Lee SJ, Choe HS, Giacobbe DR. Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance. Biomed Res Int. 2018;2018. https:\/\/doi.org\/10.1155\/2018\/7656752","DOI":"10.1155\/2018\/7656752"},{"issue":"2","key":"1839_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JU.0000000000000509","volume":"203","author":"DJ Lightner","year":"2020","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203(2):351\u20136. https:\/\/doi.org\/10.1097\/JU.0000000000000509.","journal-title":"J Urol"},{"key":"1839_CR17","unstructured":"Bonkat G, Bartoletti R, Bruy\u00e8re F et al. EAU Guidelines on Urological Infections. Eur Assoc Urol. 2024. 2024;(March):1-184."},{"issue":"10","key":"1839_CR18","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s10096-017-3007-7","volume":"36","author":"Z Huang","year":"2017","unstructured":"Huang Z, Xiao H, Li H, Yan W, Ji Z. Analysis of the incidence and risk factors of male urinary tract infection following urodynamic study. Eur J Clin Microbiol Infect Dis. 2017;36(10):1873\u20138. https:\/\/doi.org\/10.1007\/s10096-017-3007-7.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"1839_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.urols.2016.11.010","volume":"28","author":"M Nadeem","year":"2017","unstructured":"Nadeem M, Sheikh MI, Sait MS, Emmanuel N, Sheriff MKM, Masood S. Is urinary tract infection after urodynamic study predictable? Urol Sci. 2017;28(4):240\u20132. https:\/\/doi.org\/10.1016\/j.urols.2016.11.010.","journal-title":"Urol Sci"},{"issue":"1","key":"1839_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2009.10.001","volume":"22","author":"TM Robertson","year":"2010","unstructured":"Robertson TM, Hamlin AS, Urodynamics. Crit Care Nurs Clin North Am. 2010;22(1):109\u201320. https:\/\/doi.org\/10.1016\/j.ccell.2009.10.001.","journal-title":"Crit Care Nurs Clin North Am"},{"issue":"2","key":"1839_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1590\/S1677-5538.IBJU.2018.0574","volume":"45","author":"MT da Silva","year":"2019","unstructured":"da Silva MT, Barboza AL, Pijo\u00e1n MM, Beraldo PSS. Antibiotic prophylaxis prior to urodynamic study in patients with traumatic spinal cord injury. Is there an indication? Int Braz J Urol. 2019;45(2):347\u201353. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2018.0574.","journal-title":"Int Braz J Urol"},{"issue":"1","key":"1839_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/sc.2012.107","volume":"51","author":"R B\u00f6thig","year":"2013","unstructured":"B\u00f6thig R, Fiebag K, Thietje R, Faschingbauer M, Hirschfeld S. Morbidity of urinary tract infection after urodynamic examination of hospitalized SCI patients: the impact of bladder management. Spinal Cord. 2013;51(1):70\u20134. https:\/\/doi.org\/10.1038\/sc.2012.107.","journal-title":"Spinal Cord"},{"issue":"1","key":"1839_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00192-020-04501-3","volume":"32","author":"A Benseler","year":"2021","unstructured":"Benseler A, Anglim B, Zhao ZY, Walsh C, McDermott CD. Antibiotic prophylaxis for urodynamic testing in women: a systematic review. Int Urogynecol J. 2021;32(1):27\u201338. https:\/\/doi.org\/10.1007\/s00192-020-04501-3.","journal-title":"Int Urogynecol J"},{"issue":"4","key":"1839_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/nau.23253","volume":"36","author":"AP Cameron","year":"2017","unstructured":"Cameron AP, Campeau L, Brucker BM, et al. Best practice policy statement on urodynamic antibiotic prophylaxis in the non-index patient. Neurourol Urodyn. 2017;36(4):915\u201326. https:\/\/doi.org\/10.1002\/nau.23253.","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"1839_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics9080511","volume":"9","author":"M Fajfr","year":"2020","unstructured":"Fajfr M, Balik M, Cermakova E, Bostik P. Effective treatment for uncomplicated urinary tract infections with oral fosfomycin, single center four year retrospective study. Antibiotics. 2020;9(8):1\u20139. https:\/\/doi.org\/10.3390\/antibiotics9080511.","journal-title":"Antibiotics"},{"issue":"6","key":"1839_CR26","doi-asserted-by":"publisher","first-page":"106983","DOI":"10.1016\/j.ijantimicag.2023.106983","volume":"62","author":"T Cai","year":"2023","unstructured":"Cai T, Novelli A, Tascini C, Stefani S. Rediscovering the value of fosfomycin Trometamol in the era of antimicrobial resistance: A systematic review and expert opinion. Int J Antimicrob Agents. 2023;62(6):106983. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106983.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"1839_CR27","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/jac\/dkq237","volume":"65","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1862\u201377. https:\/\/doi.org\/10.1093\/jac\/dkq237.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1839_CR28","doi-asserted-by":"publisher","first-page":"106018","DOI":"10.1016\/j.ijantimicag.2020.106018","volume":"56","author":"T Wang","year":"2020","unstructured":"Wang T, Wu G, Wang J, et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(1):106018. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106018.","journal-title":"Int J Antimicrob Agents"},{"key":"1839_CR29","doi-asserted-by":"publisher","first-page":"6661588","DOI":"10.1155\/2021\/6661588","volume":"2021","author":"XY Wu","year":"2021","unstructured":"Wu XY, Cheng Y, Xu SF, Ling Q, Yuan XY, Du GH. Prophylactic antibiotics for urinary tract infections after urodynamic studies: a meta-analysis. Biomed Res Int. 2021;2021:6661588.","journal-title":"Biomed Res Int"},{"key":"1839_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00192-020-04501-3","volume":"32","author":"A Benseler","year":"2021","unstructured":"Benseler A, Anglim B, Zhao ZY, Walsh C, McDermott CD. Antibiotic prophylaxis for urodynamic testing in women: a systematic review. Int Urogynecol J. 2021;32:27\u201338.","journal-title":"Int Urogynecol J"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01839-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:09:30Z","timestamp":1781604570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-01839-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01839-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has received institutional approval under Ethical Clearance number LB.02.01\/VII.01\/47374\/01\/2023 issued by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia and under Ethical Clearance number 89\/KEPK-RSUPP\/05\/2023 issued by the Ethics Committee of Health Research of Persahabatan Hospital. Written informed consent was obtained from all participants prior to the start of the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"2023-08-24.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study registration date"}},{"value":"The study was registered with ClinicalTrials.gov under registration number NCT06017479. The full trial protocol is available on ClinicalTrials.gov (NCT06017479) or as Supplementary Material attached to this article. This study adheres to the CONSORT guidelines for reporting randomized controlled trials. A completed CONSORT checklist has been provided as a supplementary file.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study registration date"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}